Metraipolis › archive › dc_6b027f73da94

Real-World Outcomes of Baricitinib Monotherapy Versus csDMARD Combination Therapy in Rheumatoid Arthritis: A SingleCenter Retrospective Analysis of Efficacy,… — Europe PMC PMID:40963337

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40963337
DOI
10.5152/archrheumatol.2025.11131
License (as archived)
solo-consultazione
Archived
2026-11-10T05:23:37.639Z
SHA-256 of the archived text
4031945095988b6d1d5ef25df0c2984fbcc096592142ed50f2e6d1b890964fe4
Stable URL of this page
https://metraipolis.com/documento/dc_6b027f73da94

How to cite

Real-World Outcomes of Baricitinib Monotherapy Versus csDMARD Combination Therapy in Rheumatoid Arthritis: A SingleCenter Retrospective Analysis of Efficacy,… — Europe PMC PMID:40963337 — Europe PMC (en), https://europepmc.org/article/MED/40963337 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6b027f73da94 (Metraipolis archive dc_6b027f73da94, sha256 4031945095988b6d1d5ef25df0c2984fbcc096592142ed50f2e6d1b890964fe4)
BibTeX
@misc{dc6b027f73da94,
  title = {Real-World Outcomes of Baricitinib Monotherapy Versus csDMARD Combination Therapy in Rheumatoid Arthritis: A SingleCenter Retrospective Analysis of Efficacy,… — Europe PMC PMID:40963337},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40963337},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6b027f73da94; sha256 4031945095988b6d1d5ef25df0c2984fbcc096592142ed50f2e6d1b890964fe4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40963337. Agents can read the archived copy with the MCP tool read_document.